Mycosis Fungoides – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Mycosis Fungoides – Drugs In Development, 2024 report and make more profitable business decisions.
Mycosis fungoides is a rare type of non-Hodgkin lymphoma, specifically a subtype of cutaneous T-cell lymphoma (CTCL), which primarily affects the skin. It is characterized by the abnormal accumulation of malignant T-cells (a type of white blood cell) in the skin, leading to various skin symptoms and, in advanced stages, potential involvement of other organs. Mycosis fungoides is the most common type of CTCL, though it remains relatively rare overall. It typically affects adults, with an average age of onset around 55-60 years, though it can occur at any age, including childhood. The disease progresses slowly over years. Initial symptoms may include red, scaly patches on the skin (known as patches or plaques) that may resemble eczema or psoriasis. These lesions are usually itchy but can vary in appearance. Over time, the disease can progress to more defined tumors, ulcers, or nodules on the skin. In advanced cases, lymph nodes and internal organs may become involved. Diagnosis of mycosis fungoides involves a combination of clinical evaluation, skin biopsy, and sometimes additional tests like blood work, imaging studies (X-rays, CT scans, or PET scans), or a lymph node biopsy to determine the extent of the disease.
The Mycosis Fungoides drugs in development market research report provide comprehensive information on the therapeutics under development for Mycosis Fungoides, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mycosis Fungoides and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Mycosis Fungoides | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 41 molecules, with 39 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Mycosis Fungoides therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Mycosis Fungoides pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Mycosis Fungoides treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
4SC AGAB Science SA
AbbVie Inc
Affimed GmbH
AstraZeneca Plc
Beijing Boren Hospital
BioInvent International AB
Bristol-Myers Squibb Co
Celldex Therapeutics Inc
Citius Pharmaceuticals Inc
CRISPR Therapeutics AG
CSPC Pharmaceutical Group Ltd
CTI BioPharma Corp
CytomX Therapeutics Inc
F. Hoffmann-La Roche Ltd
Galderma SA
Helsinn Healthcare SA
Innate Pharma SA
Kyowa Kirin Co Ltd
MedC Biopharma Ltd
Medivir AB
Merck & Co Inc
Merck KGaA
Moleculin Biotech Inc
MorphoSys AG
National Cancer Institute US
Onco Therapies Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Revolution Medicines Inc
Sanofi
SciTech Development LLC
Seagen Inc
SIRPant Immunotherapeutics Inc
Soligenix Inc
Sorrento Therapeutics Inc
Vyriad Inc
West Lake Biomedical Technology (Hangzhou) Co Ltd
Wuhan Bio-Raid Biotechnology Co Ltd
Yakult Honsha Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Mycosis Fungoides reports